Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Wall Street Futures Rise Ahead of JOLTS Data, Nike Earnings, and U.S.-Iran Talks 
Asian Currencies Stay Under Pressure as Dollar Holds Near 13-Month High Ahead of U.S. Jobs Report 
South Korea Warns Won Is Undervalued, Boosts FX Coordination With Japan 
US Resumes Dollar Shipments to Iraq After Months-Long Suspension 
Morgan Stanley Names BAE Systems Top European Defence Stock Despite Lower Price Target 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
India Manufacturing PMI Slows in June as Demand Weakens Despite Lower Cost Pressures 
U.S. Stocks End Q2 Higher as Strong Jobs Data and AI Rally Lift Wall Street 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
US Egg Producers Settle Price Manipulation Probe, Agree to Pay $3.3 Million and Donate 53 Million Eggs 
UN Chief Urges Nations to Close $100 Million UNRWA Funding Gap 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
NATO Albania Summit Faces Uncertainty as Trump, Defense Spending Concerns Loom 
Gold Price Holds Above $4,000 as Fed Rate Hike Expectations and U.S. Jobs Data Weigh on Market 
Asian Currencies Slip as Dollar Holds Firm, Yen Near Four-Decade Low Ahead of Fed, Jobs Data 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
